These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
16. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial. Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701 [TBL] [Abstract][Full Text] [Related]
17. Interferon and lamivudine combination therapy versus lamivudine monotherapy for hepatitis B e antigen-negative hepatitis B treatment: a meta-analysis of randomized controlled trials. Shi Y; Wu YH; Shu ZY; Zhang WJ; Yang J; Chen Z Hepatobiliary Pancreat Dis Int; 2010 Oct; 9(5):462-72. PubMed ID: 20943454 [TBL] [Abstract][Full Text] [Related]
18. Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study. Huang Z; Deng H; Zhao Q; Zheng Y; Peng L; Lin C; Zhao Z; Gao Z Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1165-9. PubMed ID: 23571612 [TBL] [Abstract][Full Text] [Related]
19. A randomized controlled trial of sequential pegylated interferon-α and telbivudine or vice versa for 48 weeks in hepatitis B e antigen-negative chronic hepatitis B. Piccolo P; Lenci I; di Paolo D; Demelia L; Sorbello O; Nosotti L; Angelico M Antivir Ther; 2013; 18(1):57-64. PubMed ID: 22872648 [TBL] [Abstract][Full Text] [Related]
20. Viral dominance patterns in chronic hepatitis delta determine early response to interferon alpha therapy. Lutterkort GL; Wranke A; Hengst J; Yurdaydin C; Stift J; Bremer B; Hardtke S; Keskin O; Idilman R; Manns MP; Dienes HP; Falk C; Wedemeyer H; Heidrich B J Viral Hepat; 2018 Nov; 25(11):1384-1394. PubMed ID: 29888837 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]